Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Jun 2019 to Jun 2024
Stratagene Corporation (Nasdaq:STGN), a developer,
manufacturer and marketer of specialized life science research and
diagnostics products, announced today that it has entered into a joint
development and license agreement with Rosetta Inpharmatics LLC, a
wholly-owned subsidiary of Merck & Co., Inc., to create an automated
solution for the isolation of nucleic acids from a variety of clinical
samples. Nucleic acid purification allows researchers to separate RNA
contained in biological samples. Clinicians and researchers can use
the purified RNA to perform gene expression analysis and other
functions within molecular diagnostics.
Under the terms of the agreement, Stratagene and Rosetta will
jointly develop a proprietary instrument and a single-use consumable
that will be manufactured and commercialized by Stratagene. These
products will be sold to Stratagene's current customer base and
companies engaged in pharmacogenomics. Financial terms of the
agreement were not disclosed.
"This agreement with Rosetta Inpharmatics is a significant
opportunity for Stratagene and marks another milestone in our
molecular diagnostics strategy," said Joseph A. Sorge, MD, President
and CEO of Stratagene. "We believe we have a unique opportunity to
create and introduce a differentiated product that will automate the
RNA purification process and provide consistent, reproducible results.
These two characteristics are critical capabilities in gene expression
analysis."
About Stratagene Corporation
Stratagene is a developer, manufacturer and marketer of
specialized life science research and diagnostic products. The
Company's life science research unit supports advances in science by
inventing, manufacturing and distributing products that simplify,
accelerate and improve research. These products are used throughout
the academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis as well as high quality automated instrument
and reagent systems that use blood samples to test for more than 1,000
different allergies and autoimmune disorders. In addition, by
combining its expertise in diagnostics and molecular biology, as well
as its experience with FDA regulatory procedures, the Company is
pursuing opportunities to expand its product portfolio to include
molecular diagnostic kits and instrumentation. More information is
available at www.stratagene.com.
Safe Harbor Statement
Certain statements in this news release that are not historical
fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Stockholders and
other readers are cautioned not to place undue reliance on these
forward-looking statements. Stratagene generally identifies
forward-looking statements by using words like "believe," "intend,"
"target," "expect," "estimate," "may," "should," "plan," "project,"
"contemplate," "anticipate," "predict" or similar expressions. You can
also identify forward-looking statements by discussions of strategies,
plans or intentions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
actual results of Stratagene to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. Among the important factors that could
cause actual results to differ materially from those contained in or
implied by the forward-looking statements are risks associated with
the company's inability to sufficiently anticipate market needs and
develop products and product enhancements that achieve market
acceptance, the company's ability to compete effectively in the
diagnostics and life science research markets, variability of the
company's quarterly revenues and operating results, the failure of the
company to retain key employees, the company's ability to obtain
additional debt or equity financing, the possibility of declining
sales due in part to a reduction in research and development budgets
or government funding, the company's ongoing ability to protect its
own intellectual property rights and to avoid violating the
intellectual property rights of third parties, extended manufacturing
difficulties and currency fluctuations. For more information about
these and other factors that could cause actual results to differ
materially from those contained in or implied by the forward-looking
statements please see Item "1A. Risk Factors" included in Stratagene's
Annual Report on Form 10-K for the year ended December 31, 2005 and in
other reports filed by Stratagene from time to time with the
Securities and Exchange Commission, including Quarterly Reports on
Form 10-Q.